Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 13Nausea 6Neoplasms 5Multiple Myeloma 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Melanoma 1Gynecologic Cancer 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Cisplatin 5Docetaxel 4Brachytherapy 4Pemetrexed 3Gemcitabine 3Doxorubicin 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2Letrozole 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uterine Neoplasms × fosaprepitant × Clear all
NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡